Comparative Pharmacology
Head-to-head clinical analysis: DELALUTIN versus NORETHINDRONE AND ETHINYL ESTRADIOL 10 11.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELALUTIN versus NORETHINDRONE AND ETHINYL ESTRADIOL 10 11.
DELALUTIN vs NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestogen; suppresses gonadotropin secretion, induces secretory endometrium, inhibits uterine contractions.
Combination oral contraceptive; ethinyl estradiol suppresses follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, inhibiting ovulation; norethindrone alters cervical mucus, endometrial lining, and sperm penetration.
Hydroxyprogesterone caproate: 250-500 mg IM weekly, starting at 16-20 weeks gestation and continuing until 37 weeks or delivery, for prevention of preterm birth in women with singleton pregnancy and prior spontaneous preterm birth.
One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg for days 1-10; norethindrone 1 mg/ethinyl estradiol 35 mcg for days 11-21) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
None Documented
None Documented
Terminal elimination half-life approximately 5.5 days (range 3-7 days), supporting weekly intramuscular dosing for sustained progestational effect.
Norethindrone: terminal half-life ~7-8 hours. Ethinyl estradiol: terminal half-life ~13-27 hours (mean ~17 hours). Clinical context: Steady-state achieved within ~5-10 days; dosing interval based on maintaining contraceptive efficacy.
Primarily renal; conjugated metabolites excreted in urine (50-60%) and bile/feces (30-40%).
Norethindrone and ethinyl estradiol are primarily eliminated via renal excretion. Norethindrone is excreted as glucuronide and sulfate conjugates, with ~50% renal and ~20-30% fecal. Ethinyl estradiol is extensively metabolized; ~40% renal and ~60% fecal as conjugates.
Category C
Category D/X
Progestin
Progestin